Browse
Browse
Home
People
Organizations
Research
Events
Capability Map
UAB 18106:OXEL: A pilot study of immune checkpoint or capecitabine or combination therapy as adjuvant therapy for triple negative breast cancer with residual disease following neoadjuvant chemotherapy
Grant
Overview
Affiliation
Overview
Awarded By
Georgetown University
Total Award Amount
26696.00
Direct Costs
20535.00
Sponsor Award Id
Affiliation
Contributor
Erica Stringer-Reasor M.D.
Principal Investigator